Operating Lease, Right-of-Use Asset of Seres Therapeutics, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Seres Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Seres Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $74,669,000, a 9.9% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Seres Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $74,669,000 -$8,241,000 -9.9% 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $76,794,000 -$26,488,000 -26% 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $78,858,000 -$26,811,000 -25% 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $80,903,000 -$9,514,000 -11% 31 Dec 2024 10-Q 05 Nov 2025 2025 Q3
Q3 2024 $82,910,000 -$25,195,000 -23% 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $103,282,000 -$7,001,000 -6.3% 30 Jun 2024 10-Q 13 Aug 2024 2024 Q2
Q1 2024 $105,669,000 -$3,245,000 -3% 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $90,417,000 -$20,567,000 -19% 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $108,105,000 +$84,358,000 +355% 30 Sep 2023 10-Q 02 Nov 2023 2023 Q3
Q2 2023 $110,283,000 +$85,282,000 +341% 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $108,914,000 +$82,668,000 +315% 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $110,984,000 +$92,776,000 +510% 31 Dec 2022 8-K 15 Aug 2024
Q3 2022 $23,747,000 +$12,159,000 +105% 30 Sep 2022 10-Q 02 Nov 2022 2022 Q3
Q2 2022 $25,001,000 +$12,586,000 +101% 30 Jun 2022 10-Q 03 Aug 2022 2022 Q2
Q1 2022 $26,246,000 +$17,860,000 +213% 31 Mar 2022 10-Q 04 May 2022 2022 Q1
Q4 2021 $18,208,000 +$9,167,000 +101% 31 Dec 2021 10-K 07 Mar 2023 2022 FY
Q3 2021 $11,588,000 +$1,924,000 +20% 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $12,415,000 +$2,158,000 +21% 30 Jun 2021 10-Q 03 Aug 2021 2021 Q2
Q1 2021 $8,386,000 -$2,434,000 -22% 31 Mar 2021 10-Q 04 May 2021 2021 Q1
Q4 2020 $9,041,000 -$2,315,000 -20% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $9,664,000 -$2,235,000 -19% 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $10,257,000 -$2,383,000 -19% 30 Jun 2020 10-Q 28 Jul 2020 2020 Q2
Q1 2020 $10,820,000 -$2,382,000 -18% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $11,356,000 31 Dec 2019 10-K 02 Mar 2021 2020 FY
Q3 2019 $11,899,000 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 $12,640,000 30 Jun 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 $13,202,000 31 Mar 2019 10-Q 02 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.